Insights about U.S. Stocks that landed in the Red-Zone during Thursday’s trade, are depicted underneath:

Ibio Inc (NYSEMKT:IBIO)’s shares dwindled -4.02%, and closed at $0.840.

Formerly on February 25, iBio, Inc. (IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, declared the issue of US patent serial No. 8,962,278 titled “COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS.” The patent will join patent family members formerly issued in China, India, Korea and Europe.

“This technology continues the expansion of iBio’s antibody portfolio and broadens our patent protection for product candidates addressing anthrax, both for natural outbreaks and for possible biodefense considerations,” said Wayne P. Fitzmaurice Ph.D., iBio’s Vice President, Intellectual Property. “These monoclonal antibodies will complement our vaccine technology such as is described in our U.S. patent 8,277,816 covering compositions of matter and methods of producing and formulating anthrax vaccines.”

Claims involve human monoclonal antibodies specifically recognizing the Protective Antigen (PA) or the Lethal Factor (LF) of Bacillus anthracis, the bacteria causing anthrax. In mouse and non-human primate studies such antibodies, produced with the use of iBio’s iBioLaunch™ gene expression platform technology, prevented death in 100% of animals given an otherwise lethal doses of anthrax spores.

In addition to its proprietary fibrosis therapeutic program and the production of monoclonal antibody candidates, iBio is exploring the commercialization of its iBioLaunch gene expression platform technology for viral and bacterial infectious disease applications through collaborations with third parties. The corporation’s technology has been successfully applied to the development of an anthrax vaccine candidate, and a Phase 1 clinical trial of the safety and immunogenicity of this experimental vaccine, produced at the Fraunhofer USA Center for Molecular Biotechnology under a research license from iBio, is being conducted at Walter Reed Army Institute of Research. The clinical trial is projected to be accomplished in July 2015 (ClinicalTrials.gov Identifier: NCT02239172). Funding for this vaccine program was awarded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in December 2012.

iBio, Inc., a biotechnology corporation, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally.

Mast Therapeutics Inc (NYSEMKT:MSTX) declined -3.97%, and closed at $0.551.

Mast Therapeutics, Inc. (MSTX), declared preliminary findings from a randomized, placebo-controlled, nonclinical study of vepoloxamer (MST-188) in a model of chronic, stable heart failure produced by intracoronary microembolizations. The primary objective of this study was to examine the effects of repeat intravenous administration of vepoloxamer on left ventricular (LV) systolic and diastolic function.

• Study reproduced earlier findings that a single, 2-hour intravenous administration of vepoloxamer resulted in robust improvements in key parameters of heart function that persisted for up to 2 weeks
• New findings demonstrated that retreatment at 3 weeks resulted in improvements in ventricular function similar to the first administration and that the treatment effect was sustained for at least 3 additional weeks (to end of 6-week study).

Mast Therapeutics, Inc., a biopharmaceutical corporation, focuses on developing therapies for serious or life-threatening diseases. It primarily develops MST-188, a phase III product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties for the treatment of sickle cell disease in patients.

Callon Petroleum Company (NYSE:CPE) dipped -3.89%, and closed at $7.16.

Callon Petroleum Corporation (CPE), stated results of operations for the three and twelve month periods ended December 31, 2014.

The Corporation highlighted financial and operating results for the fourth quarter of 2014:

• Net daily production of 7,270 barrels of oil equivalent per day (“BOE/d”), an raise of 29% over the third quarter of 2014, comprised of 79% oil volume.
• Adjusted EBITDA and discretionary cash flow, non-GAAP financial measures(i), of $32.9 million and $27.6 million, respectively.
• “Drill-bit” finding and development costs(ii) of $13.91 per barrel of oil equivalent (“BOE”) for the year ended December 31, 2014 related to a 15.7 million BOE raise in total proved reserves which resulted in the replacement of 759% of 2014 production volumes.

Operating and Financial Results:

Total Proceed. For the quarter ended December 31, 2014, Callon stated total proceeds of $38.4 million, not including the $7.1 million influence of settled derivative contracts, comprised of oil proceeds of $34.4 million and natural gas proceeds of $4.0 million. Average daily production for the quarter was 7,270 BOE/d contrast to average daily production of 5,641 BOE/d in the third quarter of 2014. As discussed in the Corporation’s preceding operations update release, weather conditions at the end of December 2014 adversely influenced sales volumes for the quarter. Average realized prices were $65.05 per barrel of oil and $4.78 per Mcf of natural gas in the fourth quarter of 2014, representing a weighted average of $57.44 per BOE produced, not including the influence of settled derivative contracts.

As of December 31, 2014, the Corporation had total liquidity of $216 million, counting $215 million of credit facility availability.

Callon Petroleum Corporation is an independent energy corporation focused on the attainment, development, exploration, and operation of oil and gas properties in the Permian Basin in West Texas.

Wayfair Inc (NYSE:W), dropped -3.88%, and closed at $27.78.

Wayfair Inc. (W): Canaccord’s price target raise to $36 from $34, and with an unchanged “buy” rating. In its fourth quarter, Wayfair’s direct retail proceed grew 55% year over year to $347 million, beating analysts’ estimates of $302 million.

“Administration commented that the greatest influence on the quarter came from better engagement, repeat behavior, and customer attainment,” Canaccord said.

Wayfair’s emphasis on holiday and seasonal product drove upside for the corporation, analysts said, adding that the home good e-tailer had 250k discounted target items, with 10k featured in gift guides, and 5% deeper savings than in the previous year.

“Despite adding a record number of new customers in its fourth quarter of 2014, quarterly orders per active customer still raised 17% sequentially to 56 cents per share from 48 cents per share,” Canaccord noted.

The firm raised its 2015 fiscal year proceed estimates to $1.7 billion from $1.6 billion.

Wayfair Inc. engages in the e-commerce business in the United States. The corporation primarily offers furniture, décor, lighting, kitchen, bed and bath, outdoor, home improvement, and baby and kids products under the Wayfair.com, Joss & Main, AllModern, DwellStudio, and Birch Lane brands. It also sells its products through retail partners.